Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer–Specific Mortality in a Large Nationwide Cohort. Issue 4 (20th July 2021)

• Record Type: Journal Article
• Authors: Liao, Shu‐Fen; Koshiol, Jill; Huang, Yi‐Hsiang; Jackson, Sarah S.; Huang, Yu‐Han; Chan, Chi; Huang, Claire; Liu, Po‐Chun; Chen, Yen‐Ju; Hsieh, Rebecca J.; Huang, Ching‐Po; Lu, Sheng‐Nan; Chen, Chien‐Jen; Shen, Chen‐Yang; Lee, Mei‐Hsuan
• Is Part Of: Hepatology. Volume 74:Issue 4(2021)
• Page Start: 1994
• Page End: 2006
• Publication Date: 2021-07-20
• Subjects: Heart -- Diseases -- Nursing -- Periodicals; Lungs -- Diseases -- Nursing -- Periodicals; Intensive care nursing -- Periodicals; Foie -- Maladies -- Périodiques; 616.362
• DOI: 10.1002/hep.31879
• Languages: English
• ISSNs: 0270-9139

Abstract

Abstract : Background and Aims: Biliary tract cancer (BTC) is rare and has limited treatment options. We aimed to examine aspirin use on cancer‐specific survival in various BTC subtypes, including gallbladder cancer, ampulla of Vater cancer, and cholangiocarcinoma. Approach and Results: Nationwide prospective cohort of newly diagnosed BTC between 2007 and 2015 were included and followed until December 31, 2017. Three nationwide databases, namely the Cancer Registration, National Health Insurance, and Death Certification System, were used for computerized data linkage. Aspirin use was defined as one or more prescriptions, and the maximum defined daily dose was used to evaluate the dose–response relationship. Cox's proportional hazards models were applied for estimating HRs and 95% CIs. Analyses accounted for competing risk of cardiovascular deaths, and landmark analyses to avoid immortal time bias were performed. In total, 2, 519 of patients with BTC were exposed to aspirin after their diagnosis (15.7%). After a mean follow‐up of 1.59 years, the 5‐year survival rate was 27.4%. The multivariate‐adjusted HR for postdiagnosis aspirin users, as compared with nonusers, was 0.55 (95% CI: 0.51 to 0.58) for BTC‐specific death. Adjusted HRs for BTC‐specific death were 0.53 (95% CI: 0.48 to 0.59) and 0.42 (95% CI: 0.31 to 0.58) for ≤ 1 and > 1 maximum defined daily dose, respectively, and showed a dose–response trend ( P < 0.001; nonusers as a reference). Cancer‐specific mortality was lower with postdiagnosis aspirin use in patients with all major BTC subtypes. Conclusions: The nationwide study revealed that postdiagnosis aspirin use was associated with improved BTC‐specific mortality of various subtypes. The findings suggest that additional randomized trials are required to investigate aspirin's efficacy in BTC.